IPO filing research

BlossomHill Therapeutics, Inc.

Pharmaceutical Preparations

ipo amended Nasdaq Global Select Market S-1

BlossomHill Therapeutics, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-07-17. Current deal snapshot: exchange Nasdaq Global Select Market.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Common Stock · Exchange Nasdaq Global Select Market · Ticker BLSM · Use of proceeds Proceeds will be used for general corporate purposes, including working capital and research and development · Underwriters J.P. Morgan, Leerink Partners, Guggenheim Securities

BlossomHill Therapeutics, Inc. is conducting an IPO to raise capital through the sale of common stock. The filing outlines the use of net proceeds for short-term investments and details capitalization changes, including the automatic conversion of convertible preferred stock into common stock. Pro forma financial tables illustrate the impact of the offering on the company's balance sheet, with emphasis on dilution risks for new investors. The document highlights the company's historical net tangible book value deficit and potential dilution from the IPO.

2026-07-17 · 0001193125-26-306506

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

2026-06-11 · 0001193125-26-267857

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2026-04-24 · 0001193125-26-177693

Comparable Deals

17 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 17 using nearest neighbors.

Showing top 8 by similarity.

-8.2%

Median day-1

47%

Above issue

-2.1%

Median week-1

-20.9%

Downside (p10)

Kardigan, Inc. KARD

2026-06-18 $400M Day 1: +37.5% Wk 1: +41.1%

same SICrecent IPO

Parabilis Medicines, Inc. PBLS

2026-06-10 $670M Day 1: +58.0% Wk 1: +30.2%

same SICrecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SICrecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SICrecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SICrecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SICrecent IPO

Standard Nuclear, Inc. STDN

2026-07-16 $150M Day 1: -8.2% Wk 1: -24.9%

same SIC grouprecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SICrecent IPO

Recent News

No recent news stored for this issuer.